Astria Therapeutics, Inc. (ATXS)

Astria Therapeutics' stock was significantly impacted by the announcement of its acquisition by BioCryst Pharmaceuticals, Inc. for approximately $700 million in a mix of cash and stock, valuing Astria at $13.00 per share. The deal, expected to close in the first quarter of 2026, led to a surge in Astria's stock price. Following the acquisition announcement, several analysts downgraded Astria Therapeutics' stock rating. As of January 7, 2026, the stock price was $13.20, an increase of 58.08% from January 8, 2025. The stock has shown some recent fluctuations, falling by -1.65% on January 13, 2026, and experiencing a -3.7% drop over the preceding 10 days.

Information regarding demand seasonality for Astria Therapeutics, Inc.'s products and services is not explicitly available. Historically, buying ATXS stock in August has shown the highest probability of a positive return, while April has the lowest probability. This seasonality relates to stock performance rather than the demand for the company's therapeutic products.

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics for allergic and immunological diseases. The company's lead product candidate is navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in Phase 1b/2 clinical trials for hereditary angioedema (HAE). Astria is also developing STAR-0310, a monoclonal antibody OX40 antagonist, in clinical development for atopic dermatitis (AD). Astria Therapeutics was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name in September 2021.

Astria Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States. The company's clinical development programs, such as the ALPHA-STAR Phase 1b/2 trial for navenibart, have been conducted globally, across multiple countries.

Astria Therapeutics' reputation has been positively influenced by strong clinical trial results and strategic developments. The company announced positive final results from the ALPHA-STAR Phase 1b/2 clinical trial of navenibart (STAR-0215) for hereditary angioedema (HAE) in November 2025. Astria Therapeutics received FDA clearance for its Investigational New Drug application for STAR-0310, an OX40 antagonist for atopic dermatitis, paving the way for a Phase 1a clinical trial in healthy volunteers in Q1 2025. There were no specific events found in the provided search results that negatively impacted Astria Therapeutics' brand reputation in the past year.

Astria Therapeutics, Inc. has significant institutional ownership, with 100.83% institutional shareholders, 24.13% Astria Therapeutics insiders, and 0.00% retail investors. Major institutional owners include Perceptive Advisors LLC, Fmr LLC, Vestal Point Capital, LP, Fcpm Iii Services B.V., Fairmount Funds Management LLC, BlackRock, Inc., Millennium Management Llc, TCG Crossover Management, LLC, Vanguard Group Inc, and VR Adviser, LLC. Clarus Lifesciences II LP is a large individual shareholder. Insider sentiment for Astria Therapeutics is positive, driven by high-impact open-market purchases from insiders.